Aerosol release, distribution, and prevention during aerosol therapy: a simulated model for infection control
Aerosol therapy is used to deliver medical therapeutics directly to the airways to treat respiratory conditions. A potential consequence of this form of treatment is the release of fugitive aerosols, both patient derived and medical, into the environment and the subsequent exposure of caregivers and...
Gespeichert in:
Veröffentlicht in: | Drug delivery 2022-12, Vol.29 (1), p.10-17 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 17 |
---|---|
container_issue | 1 |
container_start_page | 10 |
container_title | Drug delivery |
container_volume | 29 |
creator | Mac Giolla Eain, Marc Cahill, Ronan MacLoughlin, Ronan Nolan, Kevin |
description | Aerosol therapy is used to deliver medical therapeutics directly to the airways to treat respiratory conditions. A potential consequence of this form of treatment is the release of fugitive aerosols, both patient derived and medical, into the environment and the subsequent exposure of caregivers and bystanders to potential viral infections. This study examined the release of these fugitive aerosols during a standard aerosol therapy to a simulated adult patient. An aerosol holding chamber and mouthpiece were connected to a representative head model and breathing simulator. A combination of laser and Schlieren imaging was used to non-invasively visualize the release and dispersion of fugitive aerosol particles. Time-varying aerosol particle number concentrations and size distributions were measured with optical particle sizers at clinically relevant positions to the simulated patient. The influence of breathing pattern, normal and distressed, supplemental air flow, at 0.2 and 6 LPM, and the addition of a bacterial filter to the exhalation port of the mouthpiece were assessed. Images showed large quantities of fugitive aerosols emitted from the unfiltered mouthpiece. The images and particle counter data show that the addition of a bacterial filter limited the release of these fugitive aerosols, with the peak fugitive aerosol concentrations decreasing by 47.3-83.3%, depending on distance from the simulated patient. The addition of a bacterial filter to the mouthpiece significantly reduces the levels of fugitive aerosols emitted during a simulated aerosol therapy, p≤ .05, and would greatly aid in reducing healthcare worker and bystander exposure to potentially harmful fugitive aerosols. |
doi_str_mv | 10.1080/10717544.2021.2015482 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_2754997004</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_e19e0b19f2024d96a28404aaeb168213</doaj_id><sourcerecordid>2754997004</sourcerecordid><originalsourceid>FETCH-LOGICAL-c562t-98d01ba5cce910cd0bdc3f8accfdeb514ca27fb42c24ac88cc7b25a82b35f5ce3</originalsourceid><addsrcrecordid>eNp9kV1vFCEUhidGY2v1J2hIvO1UYGCH8cLYNH40aeKNXpMDHLZsmGGFmZr997LdbWNvvOHzed8D522at4xeMKroB0Z71kshLjjlrA5MCsWfNadMctZSsRLP67oy7R46aV6VsqGUKsbly-akE8OKc85Om_EScyopkowRoeA5caHMOZhlDmk6JzA5ss14h9N-T9ySw7QmcBTNt5hhu_tIgJQwLhFmdGRMDiPxKZMwebT3OpumOaf4unnhIRZ8c5zPml9fv_y8-t7e_Ph2fXV501q54nM7KEeZAWktDoxaR42znVdgrXdoJBMWeO-N4JYLsEpZ2xsuQXHTSS8tdmfN9cHXJdjobQ4j5J1OEPT9QcprDXkONqJGNiA1bPC1j8INK-BKUAGAhq0UZ131-nTw2i5mRGdrJzLEJ6ZPb6Zwq9fpTquey6Gn1eD90SCn3wuWWW_Skqf6f81rOENlqKiUPFC2trZk9I8VGNX7xPVD4nqfuD4mXnXv_n3eo-oh4gp8PgA1jZRH-JNydHqGXUzZZ5hsKLr7f42_OPG94Q</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2754997004</pqid></control><display><type>article</type><title>Aerosol release, distribution, and prevention during aerosol therapy: a simulated model for infection control</title><source>Taylor & Francis Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Mac Giolla Eain, Marc ; Cahill, Ronan ; MacLoughlin, Ronan ; Nolan, Kevin</creator><creatorcontrib>Mac Giolla Eain, Marc ; Cahill, Ronan ; MacLoughlin, Ronan ; Nolan, Kevin</creatorcontrib><description>Aerosol therapy is used to deliver medical therapeutics directly to the airways to treat respiratory conditions. A potential consequence of this form of treatment is the release of fugitive aerosols, both patient derived and medical, into the environment and the subsequent exposure of caregivers and bystanders to potential viral infections. This study examined the release of these fugitive aerosols during a standard aerosol therapy to a simulated adult patient. An aerosol holding chamber and mouthpiece were connected to a representative head model and breathing simulator. A combination of laser and Schlieren imaging was used to non-invasively visualize the release and dispersion of fugitive aerosol particles. Time-varying aerosol particle number concentrations and size distributions were measured with optical particle sizers at clinically relevant positions to the simulated patient. The influence of breathing pattern, normal and distressed, supplemental air flow, at 0.2 and 6 LPM, and the addition of a bacterial filter to the exhalation port of the mouthpiece were assessed. Images showed large quantities of fugitive aerosols emitted from the unfiltered mouthpiece. The images and particle counter data show that the addition of a bacterial filter limited the release of these fugitive aerosols, with the peak fugitive aerosol concentrations decreasing by 47.3-83.3%, depending on distance from the simulated patient. The addition of a bacterial filter to the mouthpiece significantly reduces the levels of fugitive aerosols emitted during a simulated aerosol therapy, p≤ .05, and would greatly aid in reducing healthcare worker and bystander exposure to potentially harmful fugitive aerosols.</description><identifier>ISSN: 1071-7544</identifier><identifier>EISSN: 1521-0464</identifier><identifier>DOI: 10.1080/10717544.2021.2015482</identifier><identifier>PMID: 34962221</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>aerosol therapy ; aerosol visualization ; Aerosols ; Aerosols - administration & dosage ; Aerosols - adverse effects ; Air flow ; Caregivers ; Computer Simulation ; Coronaviruses ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 - transmission ; Disease control ; Disease transmission ; Drug Delivery Systems - instrumentation ; Drug Delivery Systems - methods ; Equipment Design ; fugitive emissions ; Humans ; Infection Control - methods ; Infectious Disease Transmission, Patient-to-Professional - prevention & control ; Lasers ; Measurement techniques ; Models, Biological ; Nebulizers and Vaporizers ; Nosocomial infections ; Particle Size ; Pharmacy ; Prevention ; Respiratory diseases ; Respiratory Therapy - adverse effects ; Respiratory Therapy - instrumentation ; Respiratory Therapy - methods ; SARS-CoV-2 ; Schlieren imaging ; Severe acute respiratory syndrome coronavirus 2 ; vibrating mesh nebulizer ; Viral infections ; Visualization</subject><ispartof>Drug delivery, 2022-12, Vol.29 (1), p.10-17</ispartof><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022</rights><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2021 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c562t-98d01ba5cce910cd0bdc3f8accfdeb514ca27fb42c24ac88cc7b25a82b35f5ce3</citedby><cites>FETCH-LOGICAL-c562t-98d01ba5cce910cd0bdc3f8accfdeb514ca27fb42c24ac88cc7b25a82b35f5ce3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725970/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725970/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,27479,27901,27902,53766,53768,59116,59117</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34962221$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mac Giolla Eain, Marc</creatorcontrib><creatorcontrib>Cahill, Ronan</creatorcontrib><creatorcontrib>MacLoughlin, Ronan</creatorcontrib><creatorcontrib>Nolan, Kevin</creatorcontrib><title>Aerosol release, distribution, and prevention during aerosol therapy: a simulated model for infection control</title><title>Drug delivery</title><addtitle>Drug Deliv</addtitle><description>Aerosol therapy is used to deliver medical therapeutics directly to the airways to treat respiratory conditions. A potential consequence of this form of treatment is the release of fugitive aerosols, both patient derived and medical, into the environment and the subsequent exposure of caregivers and bystanders to potential viral infections. This study examined the release of these fugitive aerosols during a standard aerosol therapy to a simulated adult patient. An aerosol holding chamber and mouthpiece were connected to a representative head model and breathing simulator. A combination of laser and Schlieren imaging was used to non-invasively visualize the release and dispersion of fugitive aerosol particles. Time-varying aerosol particle number concentrations and size distributions were measured with optical particle sizers at clinically relevant positions to the simulated patient. The influence of breathing pattern, normal and distressed, supplemental air flow, at 0.2 and 6 LPM, and the addition of a bacterial filter to the exhalation port of the mouthpiece were assessed. Images showed large quantities of fugitive aerosols emitted from the unfiltered mouthpiece. The images and particle counter data show that the addition of a bacterial filter limited the release of these fugitive aerosols, with the peak fugitive aerosol concentrations decreasing by 47.3-83.3%, depending on distance from the simulated patient. The addition of a bacterial filter to the mouthpiece significantly reduces the levels of fugitive aerosols emitted during a simulated aerosol therapy, p≤ .05, and would greatly aid in reducing healthcare worker and bystander exposure to potentially harmful fugitive aerosols.</description><subject>aerosol therapy</subject><subject>aerosol visualization</subject><subject>Aerosols</subject><subject>Aerosols - administration & dosage</subject><subject>Aerosols - adverse effects</subject><subject>Air flow</subject><subject>Caregivers</subject><subject>Computer Simulation</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 - transmission</subject><subject>Disease control</subject><subject>Disease transmission</subject><subject>Drug Delivery Systems - instrumentation</subject><subject>Drug Delivery Systems - methods</subject><subject>Equipment Design</subject><subject>fugitive emissions</subject><subject>Humans</subject><subject>Infection Control - methods</subject><subject>Infectious Disease Transmission, Patient-to-Professional - prevention & control</subject><subject>Lasers</subject><subject>Measurement techniques</subject><subject>Models, Biological</subject><subject>Nebulizers and Vaporizers</subject><subject>Nosocomial infections</subject><subject>Particle Size</subject><subject>Pharmacy</subject><subject>Prevention</subject><subject>Respiratory diseases</subject><subject>Respiratory Therapy - adverse effects</subject><subject>Respiratory Therapy - instrumentation</subject><subject>Respiratory Therapy - methods</subject><subject>SARS-CoV-2</subject><subject>Schlieren imaging</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>vibrating mesh nebulizer</subject><subject>Viral infections</subject><subject>Visualization</subject><issn>1071-7544</issn><issn>1521-0464</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNp9kV1vFCEUhidGY2v1J2hIvO1UYGCH8cLYNH40aeKNXpMDHLZsmGGFmZr997LdbWNvvOHzed8D522at4xeMKroB0Z71kshLjjlrA5MCsWfNadMctZSsRLP67oy7R46aV6VsqGUKsbly-akE8OKc85Om_EScyopkowRoeA5caHMOZhlDmk6JzA5ss14h9N-T9ySw7QmcBTNt5hhu_tIgJQwLhFmdGRMDiPxKZMwebT3OpumOaf4unnhIRZ8c5zPml9fv_y8-t7e_Ph2fXV501q54nM7KEeZAWktDoxaR42znVdgrXdoJBMWeO-N4JYLsEpZ2xsuQXHTSS8tdmfN9cHXJdjobQ4j5J1OEPT9QcprDXkONqJGNiA1bPC1j8INK-BKUAGAhq0UZ131-nTw2i5mRGdrJzLEJ6ZPb6Zwq9fpTquey6Gn1eD90SCn3wuWWW_Skqf6f81rOENlqKiUPFC2trZk9I8VGNX7xPVD4nqfuD4mXnXv_n3eo-oh4gp8PgA1jZRH-JNydHqGXUzZZ5hsKLr7f42_OPG94Q</recordid><startdate>202212</startdate><enddate>202212</enddate><creator>Mac Giolla Eain, Marc</creator><creator>Cahill, Ronan</creator><creator>MacLoughlin, Ronan</creator><creator>Nolan, Kevin</creator><general>Taylor & Francis</general><general>Taylor & Francis Ltd</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M2P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>202212</creationdate><title>Aerosol release, distribution, and prevention during aerosol therapy: a simulated model for infection control</title><author>Mac Giolla Eain, Marc ; Cahill, Ronan ; MacLoughlin, Ronan ; Nolan, Kevin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c562t-98d01ba5cce910cd0bdc3f8accfdeb514ca27fb42c24ac88cc7b25a82b35f5ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>aerosol therapy</topic><topic>aerosol visualization</topic><topic>Aerosols</topic><topic>Aerosols - administration & dosage</topic><topic>Aerosols - adverse effects</topic><topic>Air flow</topic><topic>Caregivers</topic><topic>Computer Simulation</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 - transmission</topic><topic>Disease control</topic><topic>Disease transmission</topic><topic>Drug Delivery Systems - instrumentation</topic><topic>Drug Delivery Systems - methods</topic><topic>Equipment Design</topic><topic>fugitive emissions</topic><topic>Humans</topic><topic>Infection Control - methods</topic><topic>Infectious Disease Transmission, Patient-to-Professional - prevention & control</topic><topic>Lasers</topic><topic>Measurement techniques</topic><topic>Models, Biological</topic><topic>Nebulizers and Vaporizers</topic><topic>Nosocomial infections</topic><topic>Particle Size</topic><topic>Pharmacy</topic><topic>Prevention</topic><topic>Respiratory diseases</topic><topic>Respiratory Therapy - adverse effects</topic><topic>Respiratory Therapy - instrumentation</topic><topic>Respiratory Therapy - methods</topic><topic>SARS-CoV-2</topic><topic>Schlieren imaging</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>vibrating mesh nebulizer</topic><topic>Viral infections</topic><topic>Visualization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mac Giolla Eain, Marc</creatorcontrib><creatorcontrib>Cahill, Ronan</creatorcontrib><creatorcontrib>MacLoughlin, Ronan</creatorcontrib><creatorcontrib>Nolan, Kevin</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Drug delivery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mac Giolla Eain, Marc</au><au>Cahill, Ronan</au><au>MacLoughlin, Ronan</au><au>Nolan, Kevin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aerosol release, distribution, and prevention during aerosol therapy: a simulated model for infection control</atitle><jtitle>Drug delivery</jtitle><addtitle>Drug Deliv</addtitle><date>2022-12</date><risdate>2022</risdate><volume>29</volume><issue>1</issue><spage>10</spage><epage>17</epage><pages>10-17</pages><issn>1071-7544</issn><eissn>1521-0464</eissn><abstract>Aerosol therapy is used to deliver medical therapeutics directly to the airways to treat respiratory conditions. A potential consequence of this form of treatment is the release of fugitive aerosols, both patient derived and medical, into the environment and the subsequent exposure of caregivers and bystanders to potential viral infections. This study examined the release of these fugitive aerosols during a standard aerosol therapy to a simulated adult patient. An aerosol holding chamber and mouthpiece were connected to a representative head model and breathing simulator. A combination of laser and Schlieren imaging was used to non-invasively visualize the release and dispersion of fugitive aerosol particles. Time-varying aerosol particle number concentrations and size distributions were measured with optical particle sizers at clinically relevant positions to the simulated patient. The influence of breathing pattern, normal and distressed, supplemental air flow, at 0.2 and 6 LPM, and the addition of a bacterial filter to the exhalation port of the mouthpiece were assessed. Images showed large quantities of fugitive aerosols emitted from the unfiltered mouthpiece. The images and particle counter data show that the addition of a bacterial filter limited the release of these fugitive aerosols, with the peak fugitive aerosol concentrations decreasing by 47.3-83.3%, depending on distance from the simulated patient. The addition of a bacterial filter to the mouthpiece significantly reduces the levels of fugitive aerosols emitted during a simulated aerosol therapy, p≤ .05, and would greatly aid in reducing healthcare worker and bystander exposure to potentially harmful fugitive aerosols.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>34962221</pmid><doi>10.1080/10717544.2021.2015482</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1071-7544 |
ispartof | Drug delivery, 2022-12, Vol.29 (1), p.10-17 |
issn | 1071-7544 1521-0464 |
language | eng |
recordid | cdi_proquest_journals_2754997004 |
source | Taylor & Francis Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
subjects | aerosol therapy aerosol visualization Aerosols Aerosols - administration & dosage Aerosols - adverse effects Air flow Caregivers Computer Simulation Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 - transmission Disease control Disease transmission Drug Delivery Systems - instrumentation Drug Delivery Systems - methods Equipment Design fugitive emissions Humans Infection Control - methods Infectious Disease Transmission, Patient-to-Professional - prevention & control Lasers Measurement techniques Models, Biological Nebulizers and Vaporizers Nosocomial infections Particle Size Pharmacy Prevention Respiratory diseases Respiratory Therapy - adverse effects Respiratory Therapy - instrumentation Respiratory Therapy - methods SARS-CoV-2 Schlieren imaging Severe acute respiratory syndrome coronavirus 2 vibrating mesh nebulizer Viral infections Visualization |
title | Aerosol release, distribution, and prevention during aerosol therapy: a simulated model for infection control |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T11%3A18%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aerosol%20release,%20distribution,%20and%20prevention%20during%20aerosol%20therapy:%20a%20simulated%20model%20for%20infection%20control&rft.jtitle=Drug%20delivery&rft.au=Mac%20Giolla%20Eain,%20Marc&rft.date=2022-12&rft.volume=29&rft.issue=1&rft.spage=10&rft.epage=17&rft.pages=10-17&rft.issn=1071-7544&rft.eissn=1521-0464&rft_id=info:doi/10.1080/10717544.2021.2015482&rft_dat=%3Cproquest_pubme%3E2754997004%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2754997004&rft_id=info:pmid/34962221&rft_doaj_id=oai_doaj_org_article_e19e0b19f2024d96a28404aaeb168213&rfr_iscdi=true |